
CLAIMS


1. A therapeutic combination which comprises a B-Raf inhibitor of Formula (I)



(I), and

a second inhibitor which is ~~a PI3 kinase inhibitor~~5-(2,6-di-morpholin-4-yl-pyrimidin-4-yl)-4-trifluoromethyl-pyridin-2-ylamine (Compound F), or a pharmaceutically acceptable salt thereof, for separate, simultaneous or sequential administration.


~~2. A therapeutic combination which comprises a B-Raf inhibitor of Formula (I)~~



~~(I); and~~

~~a second inhibitor which is a c-Met receptor tyrosine kinase inhibitor, or a pharmaceutically acceptable salt thereof, for separate, simultaneous or sequential administration.~~

~~3. A therapeutic combination which comprises a B-Raf inhibitor of Formula (I)~~



~~(I); and~~

~~a second inhibitor which is an FGFR kinase inhibitor, or a pharmaceutically acceptable salt thereof, for separate, simultaneous or sequential administration.~~

~~4~~2. The therapeutic combination according to ~~any one of claims~~ claim 1 ~~to 3~~ for use in the treatment or prevention of a proliferative disease.

~~5~~3. The therapeutic combination according claim ~~4~~ 2, wherein the proliferative disease is characterized by a V600 mutation in B-Raf.

~~6~~4. The therapeutic combination according to claim 42 or claim ~~5~~3, wherein the proliferative disease is melanoma characterized by a V600 mutation in B-Raf.

~~7~~5. Use of a therapeutic combination according to ~~any one of claims~~ claim 1 ~~to 3~~ for the preparation of a pharmaceutical composition or medicament for the treatment or prevention of a proliferative disease characterized by a V600 mutation in B-Raf.


~~8. The use according to claim 6, wherein the proliferative disease is characterized by a V600 mutation in B-Raf.~~

~~9~~6. The use according to ~~claim 6 or~~ claim ~~7~~ 5, wherein the proliferative disease is melanoma characterized by a V600 mutation in B-Raf.

~~10. The therapeutic combination of claim 1, wherein the P13 kinase inhibitor is selected from the group consisting of 2-methyl-2[4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl)-phenyl]propionitrile (Compound D), 8-(6-methoxy-pyridin-3-yl)-3-methyl-1-(4-piperazin-1-yl-3-trifluoromethyl-phenyl)-1,3-dihydroimidazo[4,5-c]quinolin-2-one (Compound E), 5-(2,6-di-morpholin-4-yl-pyrimidin-4-yl)-4-trifluoromethyl-pyridin-2-ylamine (Compound F), and (S)-pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yll-amide (Compound X).~~


~~11. The therapeutic combination of claim 1, wherein the PI3 kinase inhibitor is 5-(2,6-di-morpholin-4-yl-pyrimidin-4-yl)-4-trifluoromethyl-pyridin-2-ylamine (Compound F).~~

~~12. The therapeutic combination of claim 9, wherein the c-Met tyrosine kinase inhibitor is Compound G~~



~~(G).~~

~~13. The therapeutic combination of claim 10, wherein the FGFR kinase inhibitor is Compound H~~



~~(H).~~